CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

[1]  J. Baranda,et al.  46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors , 2022, Immuno-Oncology and Technology.

[2]  G. Basak,et al.  Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment , 2022, International journal of molecular sciences.

[3]  F. Marincola,et al.  Current strategies employed in the manipulation of gene expression for clinical purposes , 2022, Journal of Translational Medicine.

[4]  Wenbo Wang,et al.  Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential , 2022, Experimental Hematology & Oncology.

[5]  Zhenfeng Zhang,et al.  Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer , 2022, Nature Communications.

[6]  Hui Cao,et al.  Tumor buster - where will the CAR-T cell therapy ‘missile’ go? , 2022, Molecular Cancer.

[7]  Qin Dang,et al.  Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy , 2022, Theranostics.

[8]  C. Klein,et al.  Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors , 2022, Journal for ImmunoTherapy of Cancer.

[9]  A. Gafter-Gvili,et al.  Chimeric antigen receptor T‐cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis , 2022, British journal of haematology.

[10]  A. Williams,et al.  Abstract 6225: Developing a novel combination therapy using engineered chimeric antigen receptor natural killer cells targeting avsialidase with avsialidase-armed oncolytic vaccinia virus in solid tumor models , 2022, Cancer Research.

[11]  I. Papantoniou,et al.  Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital , 2022, Frontiers in Medicine.

[12]  L. Gil,et al.  Artificial intelligence and chimeric antigen receptor T-cell therapy , 2022, Acta Haematologica Polonica.

[13]  T. He,et al.  Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion , 2022, Frontiers in Oncology.

[14]  F. Yousefi,et al.  Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? , 2022, Frontiers in Immunology.

[15]  A. Naseri,et al.  Nanobody-based CAR-T cells for cancer immunotherapy , 2022, Biomarker research.

[16]  M. Coffey,et al.  Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice , 2022, Science Translational Medicine.

[17]  Zhong-chao Han,et al.  CAR-NK cells for cancer immunotherapy: from bench to bedside , 2022, Biomarker Research.

[18]  F. Ginhoux,et al.  Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer , 2022, Cell.

[19]  Dimitris N. Metaxas,et al.  In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes , 2022, PLoS Comput. Biol..

[20]  A. Bertola,et al.  Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice , 2022, International journal of molecular sciences.

[21]  Z. Zhao,et al.  Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. , 2022, Molecular immunology.

[22]  Leila A. Mashouf,et al.  CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future , 2022, Frontiers in Immunology.

[23]  Mariella G. Filbin,et al.  GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas , 2022, Nature.

[24]  D. Kaufman,et al.  iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting , 2022, Frontiers in Immunology.

[25]  C. Doglioni,et al.  Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies , 2022, Science Translational Medicine.

[26]  Z. Tian,et al.  Advances in NK cell production , 2022, Cellular & Molecular Immunology.

[27]  Yan Liang,et al.  High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma , 2022, Journal of Experimental & Clinical Cancer Research.

[28]  O. Oluwole,et al.  CAR T cell therapy in solid tumors: A review of current clinical trials , 2021, EJHaem.

[29]  Quanyin Hu,et al.  Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy , 2021, National science review.

[30]  F. Rahbarizadeh,et al.  Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic , 2021, Critical reviews in biotechnology.

[31]  M. Merad,et al.  Targeting macrophages with CAR-T cells delays solid tumor progression and enhances anti-tumor immunity , 2021, bioRxiv.

[32]  M. B. Khawar,et al.  CAR-NK Cells: From Natural Basis to Design for Kill , 2021, Frontiers in Immunology.

[33]  M. Ghanei,et al.  Dual-template rectangular nanotube molecularly imprinted polypyrrole for label-free impedimetric sensing of AFP and CEA as lung cancer biomarkers. , 2021, Talanta.

[34]  Jianfeng Zhou,et al.  Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials , 2021, Frontiers in Immunology.

[35]  D. Sheppard,et al.  Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation , 2021, Nature Communications.

[36]  A. Schambach,et al.  NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44 , 2021, Biomedicines.

[37]  A. Addeo,et al.  EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment , 2021, Nature Reviews Clinical Oncology.

[38]  T. Hyeon,et al.  Nanocomplex‐Mediated In Vivo Programming to Chimeric Antigen Receptor‐M1 Macrophages for Cancer Therapy , 2021, Advanced materials.

[39]  U. Platzbecker,et al.  Production and Application of CAR T Cells: Current and Future Role of Europe , 2021, Frontiers in Medicine.

[40]  Baoxia Liang,et al.  IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin , 2021, Journal of Hematology & Oncology.

[41]  Z. Gardanova,et al.  A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies , 2021, Stem cell research & therapy.

[42]  J. Ojemann,et al.  Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis , 2021, Nature Medicine.

[43]  M. Klichinsky,et al.  Abstract 1530: Anti-HER2 CAR monocytes demonstrate targeted anti-tumor activity and enable a single day cell manufacturing process , 2021, Immunology.

[44]  M. Klichinsky,et al.  Abstract 63: Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models , 2021, Immunology.

[45]  N. Bhattarai,et al.  CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities , 2021, Frontiers in Immunology.

[46]  A. Palmisano,et al.  Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe , 2021, Insights into Imaging.

[47]  M. Borowiec,et al.  CAR-NK Cells in the Treatment of Solid Tumors , 2021, International journal of molecular sciences.

[48]  Yuan Fang,et al.  Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients , 2021, Journal of Cancer Research and Clinical Oncology.

[49]  M. Caligiuri,et al.  An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma , 2021, Cancer Research.

[50]  Yumin Li,et al.  Reactions Related to CAR-T Cell Therapy , 2021, Frontiers in Immunology.

[51]  S. Yeap,et al.  Transfection types, methods and strategies: a technical review , 2021, PeerJ.

[52]  Fengchao Liu,et al.  The role of CD133 in hepatocellular carcinoma , 2021, Cancer biology & therapy.

[53]  F. Rahbarizadeh,et al.  Strategies for Dodging the Obstacles in CAR T Cell Therapy , 2021, Frontiers in Oncology.

[54]  Xueqiang Zhao,et al.  Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment , 2021, Cellular & Molecular Immunology.

[55]  T. Skare,et al.  ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? , 2021, Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery.

[56]  E. Ullrich,et al.  Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany , 2021, Gene Therapy.

[57]  S. Wongkham,et al.  Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells , 2021, Frontiers in Oncology.

[58]  R. Başar,et al.  GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells , 2021, Frontiers in Immunology.

[59]  H. Goldschmidt,et al.  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.

[60]  Leaf Huang,et al.  mRNA vaccine for cancer immunotherapy , 2021, Molecular cancer.

[61]  D. Powell,et al.  CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy , 2021, Nature communications.

[62]  A. Bocca,et al.  Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer , 2021, Biomedical materials.

[63]  H. Qin,et al.  αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib , 2021, Journal for ImmunoTherapy of Cancer.

[64]  Ramadan M. Hamed,et al.  Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries , 2021, The Lancet.

[65]  R. Başar,et al.  Next-generation cell therapies: the emerging role of CAR-NK cells. , 2020, Hematology. American Society of Hematology. Education Program.

[66]  Ting Zhang,et al.  Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.

[67]  A. M. Houghton,et al.  Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. , 2020, Cancer cell.

[68]  G. Church,et al.  Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions , 2020, Journal of Hematology & Oncology.

[69]  Matthew J. Frigault,et al.  Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. , 2020, Blood advances.

[70]  Zhiyuan Niu,et al.  Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity , 2020, The Journal of pathology.

[71]  T. Tonn,et al.  P06.12 Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo , 2020 .

[72]  F. Marincola,et al.  Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy , 2020, Journal for ImmunoTherapy of Cancer.

[73]  K. Benabdellah,et al.  Externally-Controlled Systems for Immunotherapy: From Bench to Bedside , 2020, Frontiers in Immunology.

[74]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[75]  H. Mirzaei,et al.  Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4 , 2020, Frontiers in immunology.

[76]  Kimberly R. Jordan,et al.  HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery , 2020, Journal for ImmunoTherapy of Cancer.

[77]  N. Rezaei,et al.  An overview of the role of interleukin-8 in colorectal cancer. , 2020, Cytokine.

[78]  A. Bazhin,et al.  Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation , 2020, Frontiers in Immunology.

[79]  L. Meng,et al.  Macrophage, the potential key mediator in CAR-T related CRS , 2020, Experimental Hematology & Oncology.

[80]  S. Badeti,et al.  Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways , 2020, Molecular therapy. Methods & clinical development.

[81]  Cai Zhang,et al.  Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy , 2020, Frontiers in Immunology.

[82]  D. Powell,et al.  CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape , 2020, Frontiers in Immunology.

[83]  R. Kiessling,et al.  Genetically modified immune cells targeting tumor antigens. , 2020, Pharmacology & therapeutics.

[84]  M. Ferrari,et al.  Emerging Technologies for Local Cancer Treatment , 2020, Advanced therapeutics.

[85]  J. Roliński,et al.  CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer , 2020, Journal of clinical medicine.

[86]  D. Oh,et al.  Antibody-secreting macrophages generated using CpG-free plasmid eliminate tumor cells through antibody-dependent cellular phagocytosis , 2020, BMB reports.

[87]  S. Jagannath,et al.  Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. , 2020, Clinical lymphoma, myeloma & leukemia.

[88]  C. Cohen,et al.  Targeting glycosylated antigens on cancer cells using siglec‐7/9‐based CAR T‐cells , 2020, Molecular carcinogenesis.

[89]  P. Lu,et al.  A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis. , 2020, Molecular immunology.

[90]  J. Maher,et al.  CAR T-cell immunotherapy of B-cell malignancy: the story so far , 2020, Therapeutic advances in vaccines and immunotherapy.

[91]  N. Okada,et al.  Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold , 2020, Cells.

[92]  E. Dolgin.  Cancer-eating immune cells kitted out with CARs , 2020, Nature Biotechnology.

[93]  S. Uddin,et al.  Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches , 2020, Cancers.

[94]  Xiaohu Zheng,et al.  LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer , 2020, Molecular therapy oncolytics.

[95]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[96]  L. Moretta,et al.  Comprehensive Phenotyping of Human PB NK Cells by Flow Cytometry , 2020, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[97]  M. Gossen,et al.  mRNA Transfection-Induced Activation of Primary Human Monocytes and Macrophages: Dependence on Carrier System and Nucleotide Modification , 2020, Scientific Reports.

[98]  Xikun Zhou,et al.  Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.

[99]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[100]  A. Schambach,et al.  Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines , 2020, Cancers.

[101]  W. Han,et al.  TGFβ inhibition via CRISPR promotes the long-term efficacy of CAR-T cells against solid tumors. , 2020, JCI insight.

[102]  Daosheng Huang,et al.  CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma , 2020, European Journal of Immunology.

[103]  R. Shaik,et al.  Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma , 2020, Cancer Immunology Research.

[104]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[105]  Pingping Shen,et al.  Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial , 2020, Oncoimmunology.

[106]  Shu Wang,et al.  CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts , 2019, Molecular therapy oncolytics.

[107]  A. Gorchakov,et al.  Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. , 2020, European urology.

[108]  Marimuthu Citartan,et al.  Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice , 2020, Frontiers in Oncology.

[109]  Jia Liu,et al.  A simple and efficient method for the generation of a porcine alveolar macrophage cell line for high-efficiency Porcine reproductive and respiratory syndrome virus 2 infection. , 2019, Journal of virological methods.

[110]  S. Zuo,et al.  Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. , 2019, Blood.

[111]  Derek E. Smith,et al.  IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients , 2019, Front. Oncol..

[112]  D. Torigian,et al.  Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  Yibing Chen,et al.  Tumor-associated macrophages: an accomplice in solid tumor progression , 2019, Journal of Biomedical Science.

[114]  A. D. De Marzo,et al.  IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer , 2019, Molecular Cancer Research.

[115]  Pingping Shen,et al.  Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix , 2019, British Journal of Cancer.

[116]  Luhong Yang,et al.  Use of immunotherapy in the treatment of gastric cancer , 2019, Oncology letters.

[117]  Junnian Zheng,et al.  CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models , 2019, Journal of immunotherapy.

[118]  D. M. Richards,et al.  Concepts for agonistic targeting of CD40 in immuno-oncology , 2019, Human vaccines & immunotherapeutics.

[119]  F. Bova,et al.  CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors , 2019, Nature Communications.

[120]  J. Gavilanes,et al.  A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts , 2019, Scientific Reports.

[121]  W. Strohl,et al.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells , 2019, Antibodies.

[122]  L. Galluzzi,et al.  Macrophages and Metabolism in the Tumor Microenvironment. , 2019, Cell metabolism.

[123]  C. Jacobson,et al.  CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions. , 2019, Journal of the National Cancer Institute.

[124]  A. Moody,et al.  HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases , 2019, Cancer Gene Therapy.

[125]  S. Matosevic,et al.  Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy , 2019, Cancers.

[126]  Yan Sun,et al.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[127]  Jianming Wu,et al.  Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy , 2019, Journal of leukocyte biology.

[128]  F. Locatelli,et al.  Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation , 2019, Front. Immunol..

[129]  J. Xu,et al.  Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. , 2019, Journal of Clinical Oncology.

[130]  B. Gorovits,et al.  Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics , 2019, BioDrugs.

[131]  Zhen Gu,et al.  Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells , 2019, Advanced materials.

[132]  E. Sala,et al.  Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel , 2019, Cancer management and research.

[133]  S. Endres,et al.  Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells , 2019, International journal of molecular sciences.

[134]  Aaron J Johnson,et al.  GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. , 2019, Blood.

[135]  Wenhan Li,et al.  Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis , 2019, Disease markers.

[136]  Bin Zhou,et al.  Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC , 2019, Journal of Immunotherapy for Cancer.

[137]  B. Shi,et al.  Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. , 2018, Journal of the National Cancer Institute.

[138]  J. Orange,et al.  Genome-wide analyses and functional profiling of human NK cell lines. , 2019, Molecular immunology.

[139]  K. Kinzler,et al.  Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome , 2018, Nature.

[140]  Xiaojing Ma,et al.  CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions , 2018, Cancer Immunology, Immunotherapy.

[141]  K. Tenbrock,et al.  Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression , 2018, Front. Immunol..

[142]  R. Alemany,et al.  CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge , 2018, Front. Immunol..

[143]  Ke Liu,et al.  FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia , 2018, Clinical Cancer Research.

[144]  É. Vivier,et al.  Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.

[145]  J. T. Afshari,et al.  Macrophage plasticity, polarization, and function in health and disease , 2018, Journal of cellular physiology.

[146]  S. Katz,et al.  Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis , 2018, Vaccines.

[147]  D. Kaufman,et al.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.

[148]  T. Kitamura,et al.  Macrophage targeting: opening new possibilities for cancer immunotherapy , 2018, Immunology.

[149]  H. Einsele,et al.  CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models , 2018, Advances in cell and gene therapy.

[150]  V. Seshan,et al.  Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo , 2018, Nature Biotechnology.

[151]  Yali Wang,et al.  Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors , 2018, Oncology letters.

[152]  W. Fisher,et al.  Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. , 2018, Cancer discovery.

[153]  F. Lin,et al.  Single and combined use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and carcinoembryonic antigen in diagnosing gastric cancer. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[154]  D. Li,et al.  Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy , 2018, Gene Therapy.

[155]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[156]  Y. Chen,et al.  TGF‐β–responsive CAR‐T cells promote anti‐tumor immune function , 2018, Bioengineering & translational medicine.

[157]  Jennifer L. Guerriero.  Macrophages: The Road Less Traveled, Changing Anticancer Therapy. , 2018, Trends in molecular medicine.

[158]  Ge Yang,et al.  Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies , 2018, Journal of immunology research.

[159]  C. June,et al.  Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager , 2018, Cancer Immunology Research.

[160]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[161]  Jun Huang,et al.  CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy. , 2018, Current opinion in chemical engineering.

[162]  D. Maloney,et al.  Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells. , 2018 .

[163]  Y. Delneste,et al.  The roles of CSFs on the functional polarization of tumor‐associated macrophages , 2018, The FEBS journal.

[164]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[165]  J. Tolar,et al.  Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T , 2018, International journal of molecular sciences.

[166]  M. Weller,et al.  NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. , 2018, Cancer research.

[167]  H. Abken,et al.  CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. , 2017, Cell reports.

[168]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[169]  A. Schambach,et al.  Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy. , 2017, Human gene therapy.

[170]  G. Ku,et al.  Systemic therapy for esophagogastric cancer: targeted therapies. , 2017, Chinese clinical oncology.

[171]  Lisa Rosenbaum.  Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy. , 2017, The New England journal of medicine.

[172]  Jeffrey W. Clark,et al.  Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer , 2017, Proceedings of the National Academy of Sciences.

[173]  G. Freeman,et al.  Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. , 2017, Cancer cell.

[174]  Guangyu Zhou,et al.  NK-92 cell, another ideal carrier for chimeric antigen receptor. , 2017, Immunotherapy.

[175]  A. Mondino,et al.  Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors. , 2017, Cytokine & growth factor reviews.

[176]  R. Grossman,et al.  HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.

[177]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[178]  Zhiqiang Wu,et al.  Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers , 2017, Protein & Cell.

[179]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[180]  Xianquan Zhang,et al.  Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[181]  J. Madrigal,et al.  Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications , 2017, Front. Immunol..

[182]  Yi Zhang,et al.  Tumor-associated macrophages: from basic research to clinical application , 2017, Journal of Hematology & Oncology.

[183]  Yangqiu Li,et al.  PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells , 2017, Oncoimmunology.

[184]  S. Albelda,et al.  CAR T Cell Therapy for Solid Tumors. , 2017, Annual review of medicine.

[185]  Yao Wang,et al.  Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma , 2017, Journal of Hematology & Oncology.

[186]  Chun Jimmie Ye,et al.  CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells , 2016, Scientific Reports.

[187]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[188]  Zhenyi Xue,et al.  CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside , 2016, Oncoimmunology.

[189]  R. Orentas,et al.  Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas , 2016, Cancer Immunology Research.

[190]  Yang Feng,et al.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. , 2016, The Journal of clinical investigation.

[191]  Toshio Tanaka,et al.  Immunotherapeutic implications of IL-6 blockade for cytokine storm. , 2016, Immunotherapy.

[192]  M. Brown,et al.  GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[193]  O. Tsitsilonis,et al.  Harnessing the immune system to improve cancer therapy. , 2016, Annals of translational medicine.

[194]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[195]  P. Allavena,et al.  Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient , 2016, Journal of Immunotherapy for Cancer.

[196]  W. Han,et al.  Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer , 2016, Science China Life Sciences.

[197]  H. Kaufman,et al.  Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy , 2015, Clinical Cancer Research.

[198]  Wendell A. Lim,et al.  Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.

[199]  Cheng-song Sun,et al.  Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy , 2015, Acta Pharmacologica Sinica.

[200]  R. Childs,et al.  Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications , 2015, Front. Immunol..

[201]  J. Bading,et al.  Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma , 2015, Clinical Cancer Research.

[202]  I. Pastan,et al.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1&agr;-secreting Glioblastoma , 2015, Journal of immunotherapy.

[203]  J. Orange,et al.  Practical NK cell phenotyping and variability in healthy adults , 2015, Immunologic Research.

[204]  Z. Tian,et al.  NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma , 2014, Cellular and Molecular Immunology.

[205]  G. Schackert,et al.  DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy , 2015, The Journal of Immunology.

[206]  R. Kaplan,et al.  4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors , 2015, Nature Medicine.

[207]  Eugene S. Kim,et al.  Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes , 2015, Nature Medicine.

[208]  Chan Hyuk Kim,et al.  Redirection of genetically engineered CAR-T cells using bifunctional small molecules. , 2015, Journal of the American Chemical Society.

[209]  I. Weissman,et al.  Macrophages are critical effectors of antibody therapies for cancer , 2015, mAbs.

[210]  A. Jauch,et al.  Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[211]  D. Spriggs,et al.  IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo , 2015, Oncoimmunology.

[212]  R. Childs,et al.  CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo , 2015, Cancer Immunology, Immunotherapy.

[213]  S. Riddell,et al.  Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.

[214]  M. Brown,et al.  Mini Review Article , 2022 .

[215]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[216]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[217]  Hao Liu,et al.  Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. , 2014, Cancer research.

[218]  H. Klingemann.  Are natural killer cells superior CAR drivers? , 2014, Oncoimmunology.

[219]  D. Dupuy,et al.  Thermal ablation of tumours: biological mechanisms and advances in therapy , 2014, Nature Reviews Cancer.

[220]  C. Rooney,et al.  Clinical grade purification and expansion of natural killer cells. , 2014, Critical reviews in oncogenesis.

[221]  E. Ponomarev,et al.  Ganglioside GD2 in reception and transduction of cell death signal in tumor cells , 2014, BMC Cancer.

[222]  B. Kaina,et al.  Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response , 2013, PloS one.

[223]  E. Puré,et al.  Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity , 2013, Cancer Immunology Research.

[224]  E. Lam,et al.  Adenovirus Detection by the cGAS/STING/TBK1 DNA Sensing Cascade , 2013, Journal of Virology.

[225]  L. Tai,et al.  Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination , 2013, Oncoimmunology.

[226]  J. Milovanović,et al.  Interleukin-8 in breast cancer progression. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[227]  Hao Liu,et al.  Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition , 2013, Clinical Cancer Research.

[228]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[229]  Y. Kew,et al.  Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[230]  Hao Liu,et al.  Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[231]  S. Ghaem-Maghami,et al.  Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin , 2013, The Journal of Immunology.

[232]  S. Rosenberg,et al.  Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. , 2013, Cancer research.

[233]  E. Rossmanith,et al.  Monocytes, Peripheral Blood Mononuclear Cells, and THP-1 Cells Exhibit Different Cytokine Expression Patterns following Stimulation with Lipopolysaccharide , 2013, Mediators of inflammation.

[234]  Xiang Du,et al.  CD133: a cancer stem cells marker, is used in colorectal cancers. , 2013, World journal of gastroenterology.

[235]  Y. Ma,et al.  Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency , 2013, Gene Therapy.

[236]  A. Galy,et al.  Vectofusin-1, a New Viral Entry Enhancer, Strongly Promotes Lentiviral Transduction of Human Hematopoietic Stem Cells , 2013, Molecular therapy. Nucleic acids.

[237]  Raphael Sandaltzopoulos,et al.  Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.

[238]  D. Kaufman,et al.  Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy , 2013, Stem cells translational medicine.

[239]  N. Landau,et al.  Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein , 2012, Gene Therapy.

[240]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[241]  X. Zhang,et al.  Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. , 2012, Cytokine.

[242]  A. Kuehnl,et al.  Impact of oxLDL and LPS on C-type Natriuretic Peptide System is Different between THP-1 Cells and Human Peripheral Blood Monocytic Cells , 2012, Cellular Physiology and Biochemistry.

[243]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[244]  S. Eccles,et al.  Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling , 2012, Journal of Clinical Immunology.

[245]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[246]  B. Sobhian,et al.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx , 2011, Nature.

[247]  S. Ferrini,et al.  Role of Common-Gamma Chain Cytokines in NK Cell Development and Function: Perspectives for Immunotherapy , 2011, Journal of biomedicine & biotechnology.

[248]  S. Rosenberg,et al.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. , 2010, The Journal of clinical investigation.

[249]  D. Kaufman,et al.  Human Pluripotent Stem Cells Produce Natural Killer Cells That Mediate Anti-HIV-1 Activity by Utilizing Diverse Cellular Mechanisms , 2010, Journal of Virology.

[250]  C. Rooney,et al.  Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b , 2010, Journal of immunotherapy.

[251]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[252]  P. Woll,et al.  Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. , 2009, Blood.

[253]  E. Andrès,et al.  CD56bright natural killer (NK) cells: an important NK cell subset , 2009, Immunology.

[254]  Fan Wang,et al.  Integrin αvβ3‐targeted cancer therapy , 2008 .

[255]  F. Farzaneh,et al.  Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. , 2008, Molecular immunology.

[256]  S. Gerber,et al.  Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.

[257]  Xiaoyuan Chen,et al.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy. , 2008, Drug development research.

[258]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[259]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[260]  D. F. Barber,et al.  Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells , 2005, The Journal of experimental medicine.

[261]  S. Karlsson,et al.  Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells , 2004, The journal of gene medicine.

[262]  M. Popp,et al.  A global view of the selectivity of zinc deprivation and excess on genes expressed in human THP-1 mononuclear cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[263]  G. Sacks,et al.  Pneumolysin-Dependent and -Independent Gene Expression Identified by cDNA Microarray Analysis of THP-1 Human Mononuclear Cells Stimulated by Streptococcus pneumoniae , 2003, Infection and Immunity.

[264]  B. Toole.  Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. , 2003, Current topics in developmental biology.

[265]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[266]  F. Marincola,et al.  Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.

[267]  M. Yarmush,et al.  Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. , 2002, Biophysical chemistry.

[268]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[269]  David A. Williams,et al.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells , 1996, Nature Medicine.

[270]  A. Billiau,et al.  Modification of the anti‐CD3‐induced cytokine release syndrome by anti‐interferon‐γ or anti‐interleukin‐6 antibody treatment: Protective effects and biphasic changes in blood cytokine levels , 1993, European journal of immunology.

[271]  G. Fleuren,et al.  Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[272]  S. Wahl,et al.  Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. , 1991, Journal of immunology.

[273]  S. Wahl,et al.  Lipopolysaccharide, tumor necrosis factor-alpha, and IL-1 beta prevent programmed cell death (apoptosis) in human peripheral blood monocytes. , 1991, Journal of immunology.

[274]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell , 1975, European journal of immunology.

[275]  JoVE Video Dataset , 2022 .